Direct and indirect impacts of the COVID-19 pandemic on patients with pulmonary and pleural malignancies – a retrospective analysis of patient outcomes treated at Department of Respiratory Diseases, University Hospital Brno, during the 2nd and 3rd coronavirus waves

Česká verzia

Authors: M. Bratová; K. Brat; L. Jakubíková
Authors place of work: Klinika nemocí plicních a tuberkulózy LF MU a FN Brno
Published in the journal: Klin Onkol 2022; 35(3): 215-221
Category: Original Articles
doi: https://doi.org/10.48095/ccko2022215

Summary

Background: The pandemic of COVID-19 has significantly influenced the diagnostics and treatment of patients with lung and pleural malignancies. This group of patients is the riskiest, compared to patients with other cancers, both in morbidity and mortality. Study population and methods: The data of patients with lung/pleural malignancies and proved COVID-19 positivity were analyzed at the Department of Respiratory Diseases and Tuberculosis, University Hospital Brno, during the period from October 2020 to May 2021. Demographic data, information about the course of SARS-CoV-2 infection and oncological disease as well as mortality were monitored. Together with the data from the study population, three case reports are also presented. Results: Fifty-three patients were found (79% males), mean age 69.4 years, mainly with adenocarcinoma histology. A total of 47.1% patients experienced mild course of SARS-CoV-2 infection, 56.6% needed hospitalization, 24.5% died. Active anticancer treatment was delayed in 62.4% cases due to SARS-CoV-2 infection; the mean time of the delay reached 14.5 days. Conclusion: Patients with lung and pleural malignancies have a high risk of severe course of SARS-CoV-2 infection and mortality. Moreover, the ongoing SARS-CoV-2 infection as well as postcovid changes can complicate the anticancer treatment itself.

Keywords:

lung cancer – mesothelioma – COVID-19 – impact on health

Zdroje

1. World Health Organization. [online]. Dostupné z: https: //www.who.int.

2. Dadras O, Afsahi AM, Pashaei Z et al. The relationship between COVID-19 viral load and disease severity: a systematic review. Immun Inflamm Dis 2022; 10 (3): e580. doi: 10.1002/iid3.580.

3. Xie C, Ding H, Ding J et al. Preparation of highly specific monoclonal antibodies against SARS-CoV-2 nucleocapsid protein and the preliminary development of antigen detection test strips. J Med Virol 2022; 94 (4): 1633–1640. doi: 10.1002/jmv.27520.

4. Rajni E, Singh A, Tarai B at al. A high frequency of Candida auris blood stream infections in coronavirus disease 2019 patients admitted to intensive care units, Northwestern India: a case control study. Open Forum Infect Dis 2021; 8 (12): 452. doi: 10.1093/ofid/ofab452.

5. Schmidt M, Guidet B, Demoule A et al. COVID-ICU investigators. Predicting 90-day survival of patients with COVID-19: survival of severely Ill COVID (SOSIC) scores. Ann Intensive Care 2021; 11 (1): 170. doi: 10.1186/s13613-021-00956-9.

6. Jajou R, Mutsaers-van Oudheusden A, Verweij JJ et al. SARS-CoV-2 transmitters have more than three times higher viral loads than non-transmitters – practical use of viral load for disease control. J Clin Virol 2022; 150–151: 105131. doi: 10.1016/j.jcv.2022.105131.

7. Koupaei M, Mohamadi MH, Yashmi I et al. Clinical manifestations, treatment options, and comorbidities in COVID-19 relapse patients: a systematic review. J Clin Lab Anal 2022; e24402. doi: 10.1002/jcla.24402.

8. Rao GSNK, Gowthami B, Naveen NR et al. An updated review on potential therapeutic drug candidates, vaccines and an insight on patents filed for COVID-19. Curr Res Pharmacol Drug Discov 2021; 2: 100063. doi: 10.1016/j.crphar.2021.100063.

9. Fani K, Ghahremani M, Fathi M et al. The effect of exogenous surfactant on moderate and severe stages of COVID-19 induced ARDS: the pilot study of a clinical trial. Iran J Pharm Res 2021; 20 (3): 553–559. doi: 10.22037/ijpr.2021.115390.15347.

10. Bierle DM, Ganesh R, Razonable RR. Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B1.617.2 (Delta) surge. J Clin Virol 2021; 145: 105026. doi: 10.1016/j.jcv.2021.105026.

11. Perry J, Osman S, Wright J et al. Does a humoral correlate of protection exist for SARS-CoV-2? A systematic review. PLoS One 2022; 17 (4): e0266852. doi: 10.1371/journal.pone.0266852.

12. Brat K, Venclicek O, Herout V et al. V. Hospitalizační léčba COVID-19. Poziční dokument České pneumologické a ftizeologické společnosti – únor 2021. Stud Pneumol Phthiseol 2021; 81 (1): 13–30.

13. Česká společnost alergologie a klinické imunologie. Doporučení pro očkování proti onemocnění covid-19 mRNA vakcínami. [online]. Dostupné z: https: //www.csaki.cz.

14. Modrá kniha. Vakcinace u dospělých pacientů se solidními nádory a profylaxe infekcí u nemocných po splenektomii. [online]. Dostupné z: https: //www.linkos.cz/files/modra-kniha/21/836.pdf.

15. Wang B, Huang Y. Which type of cancer patients are more susceptible to the SARS-COX-2: evidence from a meta-analysis and bioinformatics analysis. Crit Rev Oncol Hematol 2020; 153: 103032. doi: 10.1016/j.critrevonc.2020.103032.

16. Garassino MC, Whisenant JG, Huang LC et al. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol 2020; 21 (7): 914–922. doi: 10.1016/S1470-2045 (20) 30314-4.

17. Luo J, Rizvi H, Preeshagul IR et al. COVID-19 in patients with lung cancer. Ann Oncol 2020; 31 (10): 1386–1396. doi: 10.1016/j.annonc.2020.06.007.

18. Alkhathami MG, Advani SM, Abalkhail AA et al. Prevalence and mortality of lung comorbidities among patients with COVID-19: a systematic review and meta-analysis. Lung India 2021; 38 (Supplement): S31–40. doi: 10.4103/lungindia.lungindia_497_20.

19. Han S, Zhuang Q, Chiang J et al. Impact of cancer diagnoses on the outcomes of patients with COVID-19: a systematic review and meta-analysis. BMJ Open 2022; 12 (2): e044661. doi: 10.1136/bmjopen-2020-044661.

20. Passaro A, Bestvina C, Velez M et al. Severity of COVID-19 in patients with lung cancer: evidence and challenges. J Immunother Cancer 2021; 9 (3): 002266. doi: 10.1136/jitc-2020-002266.

21. Richardson S, Hirsch JS, Narasi M et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 2020; 323 (20): 2052–2059. doi: 10.1001/jama.2020.6775.

22. Cummings MJ, Baldwin MR, Abrams D et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet 2020; 395 (10239): 1763–1770. doi: 10.1016/S0140-6736 (20) 31189-2.

23. Lewnard JA, Liu VX, Jackson ML et al. Incidence, clinical outcomes, and transmission dynamics of severe coronavirus disease 2019 in California and Washington: prospective cohort study. BMJ 2020; 369: 1923. doi: 10.1136/bmj.m1923.

24. Fujita K, Ito T, Saito Z et al. Impact of COVID-19 pandemic on lung cancer treatment scheduling. Thorac Cancer 2020; 11 (10): 2983–2986. doi: 10.1111/1759-7714.13615.

25. Luo J, Rizvi H, Egger JV et al. Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers. Cancer Discov 2020; 10 (8): 1121–1128. doi: 10.1158/2159-8290.CD-20-0596.

26. Dai Y, Liu S, Zhang Y et al. A false alarm of COVID-19 pneumonia in lung cancer with anti-PD-1 related pneumonitis: a case report and review of the literature. J Med Case Rep 2021; 15 (1): 41. doi: 10.1186/s13256-020-02619-y.

27. Sha Z, Chang K, Mi J et al. The impact of the COVID-19 pandemic on lung cancer patients. Ann Palliat Med 2020; 9 (5): 3373–3378. doi: 10.21037/apm-20-1662.

28. Reddy R. Imaging diagnosis of bronchogenic carcinoma (the forgotten disease) during times of COVID-19 pandemic: current and future perspectives. World J Clin Oncol 2021; 12 (6): 437–457. doi: 10.5306/wjco.v12.i6.437.

29. Passaro A, Addeo A, Von Garnier C et al. ESMO management and treatment adapted recommendations in the COVID-19 era: lung cancer. ESMO Open 2020; 5 (Suppl 3): e000820. doi: 10.1136/esmoopen-2020-000820.

30. Sehgal K, Costa DB, Rangachari D. Extended-interval dosing strategy of immune checkpoint inhibitors in lung cancer: will it outlast the COVID-19 pandemic? Front Oncol 2020; 10: 1193. doi: 10.3389/fonc.2020.01193.

31. Park JY, Lee YJ, Kim T at al. Collateral effects of the coronavirus disease 2019 pandemic on lung cancer diag- nosis in Korea. BMC Cancer 2020; 20 (1): 1040. doi: 10.1186/s12885-020-07544-3.

32. Kirchberg J, Rentsch A, Klimova A et al. Influence of the first wave of the COVID-19 pandemic on cancer care in a German comprehensive cancer center. Front Public Health 2021; 9: 750479. doi: 10.3389/fpubh.2021.750479.

33. Walter JE, Heuvelmans MA, de Jong PA et al. Occurrence and lung cancer probability of new solid nodules at incidence screening with low-dose CT: analysis of data from the randomised, controlled NELSON trial. Lancet Oncol 2016; 17 (7): 907–916. doi: 10.1016/S1470-2045 (16) 30069-9.

34. Van Haren RM, Delman AM, Turner KM et al. Impact of the COVID-19 pandemic on lung cancer screening program and subsequent lung cancer. J Am Coll Surg 2021; 232 (4): 600–605. doi: 10.1016/j.jamcollsurg.2020.12.002.

35. Cantini L, Mentrasti G, Russo GL et al. Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario. ESMO Open 2022; 7 (2): 100406. doi: 10.1016/ j.esmoop.2022.100406.

36. Maringe C, Spicer J, Morris M et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncol 2020; 21 (8): 1023–1034. doi: 10.1016/S1470-2045 (20) 30388-0.

37. Bafunno D, Romito F, Lagattolla F et al. Psychological well-being in cancer outpatients during COVID-19. J BUON 2021; 26 (3): 1127–1134.

38. Walter J, Sellmer L, Kahnert K et al. Consequences of the COVID-19 pandemic on lung cancer care and patient health in a German lung cancer center: results from a cross-sectional questionnaire. Respir Res 2022; 23 (1): 18. doi: 10.1186/s12931-022-01931-z.

39. Wu M, Mou R, Liu X et al. Is COVID-19 a high risk factor for lung cancer?: a protocol for systematic review and meta-analysis. Medicine (Baltimore) 2021; 100 (1): e23877. doi: 10.1097/MD.0000000000023877.